Clinical Commander

Back to dossier
allergy.insect-bites-and-stings.core.v1PRODUCTION
allergy.insect-bites-and-stings.core.v1

Insect bites and stings (Hymenoptera, alpha-gal, non-Hymenoptera)

allergyacutechronicadultpediatric
Hard-required inputs
0 / 5
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Frame three management arcs: (1) Hymenoptera sting reactions stratified local / large local / cutaneous systemic / systemic anaphylaxis with VIT for systemic reactors; (2) alpha-gal syndrome (delayed mammalian-meat anaphylaxis via Lone Star tick exposure); (3) non-Hymenoptera bite hypersensitivity (Skeeter syndrome, papular urticaria) for symptomatic management. Acute reactions route to allergy.anaphylaxis.v1.

Inputs
0
Actions
0
Advance rule
Set
Advance when

Three-arc framing set; mastocytosis modifier and ACEi/beta-blocker comorbidity noted

Patient inputs (9)

Honey bee vs vespid vs fire ant determines VIT venom selection; in-vitro sIgE + skin testing direct selection (JTF 2016 PMID 28007086)

Local vs large local vs cutaneous systemic vs systemic anaphylaxis (Mueller / Ring classifications) gates VIT indication (JTF 2016 PMID 28007086; EAACI 2018 PMID 28748641)

Required for any patient with systemic reaction or alpha-gal; two devices recommended; technique re-taught (JTF 2016 PMID 28007086)

Children with cutaneous-only systemic reactions do NOT require VIT and are unlikely to progress; adults do; VIT pediatric / adult dosing differs (JTF 2016 PMID 28007086)

Beta-blocker may blunt epinephrine response; ACEi may augment anaphylaxis severity — counsel and consider switching when feasible (JTF 2016 PMID 28007086)

Confirm sensitisation + select VIT venom; performed >=2-4 wk post-event (refractory period) (JTF 2016 PMID 28007086)

Elevated baseline tryptase or systemic mastocytosis is the dominant anaphylaxis-fatality modifier and changes VIT duration to LIFELONG (EAACI 2018 PMID 28748641)

Diagnostic for alpha-gal syndrome — IgE to galactose-α-1,3-galactose; sensitivity high in clinical cases (Wilson 2019 PMID 30940532)

Beekeepers, farmers, gardeners, foresters, military have high re-sting probability and earn lower threshold for VIT and longer therapy (EAACI 2018 PMID 28748641)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningsystemic_anaphylaxis_post_sting
    Sting-triggered systemic reaction with airway / CV / two-organ system involvement
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremastocytosis_or_elevated_tryptase_lifelong_vit
    Baseline tryptase elevated or known mastocytosis in patient with prior systemic sting reaction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatealpha_gal_syndrome_confirmed
    Alpha-gal-specific IgE positive + history of delayed 3-6h post-mammalian-meat reaction
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatepediatric_cutaneous_systemic_no_vit
    Pediatric patient with isolated cutaneous systemic reaction (urticaria / angioedema only)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatebeta_blocker_ace_inhibitor_systemic_reactor
    Systemic reactor concurrently on beta-blocker or ACE inhibitor
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Sting/bite reaction grade-specific management + venom immunotherapy for systemic reactors
axis: sting_reaction_grade_specific_management_and_vitstep 1 - Step 1 — Local reaction (no Rx, supportive)
Selected step "Step 1 — Local reaction (no Rx, supportive)" — Localised swelling / erythema / pain at sting site, <10 cm, resolves within hours
  • ice_and_supportive_care
    first line
    supportive
    triggers: local_reaction_post_sting
    JTF 2016 (PMID 28007086) — local reactions resolve without pharmacotherapy beyond symptomatic ice/analgesia.

outpatient playbook — drug actions (5)

  1. 1. cetirizine + ice for large local
    rxcui 20610
    10 mg PO daily • PO • daily x 3-5 d
    trigger: Large local reaction (JTF 2016 PMID 28007086)
    H1 antihistamine + ice; no auto-injector / no VIT routinely
  2. 2. prednisone short burst for extensive large local
    rxcui 8640
    0.5-1 mg/kg/day • PO • short course
    trigger: Extensive large local impairing function (JTF 2016 PMID 28007086)
    Short oral steroid; not prophylactic
  3. 3. epinephrine auto-injector x 2 for cutaneous systemic (adults) and any anaphylaxis
    rxcui 3992
    0.15 / 0.3 mg IM (weight-based) • IM • PRN
    trigger: Cutaneous systemic in adult or any anaphylactic-grade event (JTF 2016 PMID 28007086)
    Rescue mainstay; two devices
  4. 4. methylprednisolone IV during ED anaphylaxis
    rxcui 6902
    1-2 mg/kg IV • IV • single ED dose
    trigger: Anaphylaxis in ED (JTF 2016 PMID 28007086)
    Adjunct in ED; never substitute for epinephrine
  5. 5. refer for venom immunotherapy 3-5 y
    per VIT schedule • SC • weekly uptitration -> monthly maintenance
    trigger: Systemic anaphylaxis with positive venom-sIgE (JTF 2016 PMID 28007086)
    Disease-modifying; reduces re-sting systemic reaction to <5%

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Hymenoptera sting (bee / vespid / fire ant) followed by urticaria / angioedema / wheeze / hypotension (JTF 2016 PMID 28007086); Large local reaction >10 cm peaking 48-72h post-sting (JTF 2016 PMID 28007086); Delayed 3-6h systemic reaction following mammalian meat (alpha-gal syndrome; Wilson 2019 PMID 30940532).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Insect bites and stings (Hymenoptera, alpha-gal, non-Hymenoptera)** (allergy.insect-bites-and-stings.core.v1).
Phenotype framing: Terminal: Hymenoptera systemic vs (alpha-gal-delayed-meat-anaphylaxis vs cardiogenic/arrhythmia mimic vs scombroid (histamine in spoiled fish, not allergy) vs vasovagal vs panic). Reaction GRADE differential (local, large local, cutaneous systemic, systemic anaphylaxis) is the primary axis driving therapy.
Scope: Frame three management arcs: (1) Hymenoptera sting reactions stratified local / large local / cutaneous systemic / systemic anaphylaxis with VIT for systemic reactors; (2) alpha-gal syndrome (delayed mammalian-meat anaphylaxis via Lone Star tick exposure); (3) non-Hymenoptera bite hypersensitivity (Skeeter syndrome, papular urticaria) for symptomatic management. Acute reactions route to allergy.anaphylaxis.v1.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Sting/bite reaction grade-specific management + venom immunotherapy for systemic reactors** — step "Step 1 — Local reaction (no Rx, supportive)".
1. ice_and_supportive_care (supportive, first line) — JTF 2016 (PMID 28007086) — local reactions resolve without pharmacotherapy beyond symptomatic ice/analgesia.

Setting playbook (outpatient) — Classify reaction grade (local / large local / cutaneous systemic / systemic anaphylaxis), prescribe grade-appropriate therapy + auto-injector + action plan, and refer systemic reactors for venom immunotherapy with lifelong VIT for high-risk groups (JTF 2016 PMID 28007086; EAACI 2018 PMID 28748641)
2. cetirizine + ice for large local 10 mg PO daily PO daily x 3-5 d — Large local reaction (JTF 2016 PMID 28007086) (H1 antihistamine + ice; no auto-injector / no VIT routinely)
3. prednisone short burst for extensive large local 0.5-1 mg/kg/day PO short course — Extensive large local impairing function (JTF 2016 PMID 28007086) (Short oral steroid; not prophylactic)
4. epinephrine auto-injector x 2 for cutaneous systemic (adults) and any anaphylaxis 0.15 / 0.3 mg IM (weight-based) IM PRN — Cutaneous systemic in adult or any anaphylactic-grade event (JTF 2016 PMID 28007086) (Rescue mainstay; two devices)
5. methylprednisolone IV during ED anaphylaxis 1-2 mg/kg IV IV single ED dose — Anaphylaxis in ED (JTF 2016 PMID 28007086) (Adjunct in ED; never substitute for epinephrine)
6. refer for venom immunotherapy 3-5 y per VIT schedule SC weekly uptitration -> monthly maintenance — Systemic anaphylaxis with positive venom-sIgE (JTF 2016 PMID 28007086) (Disease-modifying; reduces re-sting systemic reaction to <5%)

Non-pharmacologic actions:
- Written sting/bite action plan + medical-alert identification (JTF 2016 PMID 28007086)
- Hymenoptera avoidance education (do not swat, do not perfume, cover food outdoors)
- Tick-bite prevention (DEET, permethrin-treated clothing, tick check) for alpha-gal-endemic regions
- Beta-blocker / ACEi review + switch when feasible for systemic reactors (JTF 2016 PMID 28007086)
- School / workplace auto-injector plan for pediatric and high-exposure patients

AVOID / contraindication checks:
- Never substitute h1 or corticosteroid for epinephrine in systemic anaphylaxis (JTF 2016 PMID 28007086)
- Beta blocker blunts epinephrine counsel or switch when feasible (JTF 2016 PMID 28007086)
- Ace inhibitor augments anaphylaxis severity consider switching (JTF 2016 PMID 28007086)
- Vit systemic reaction risk during uptitration 30 min observation with epinephrine ready (EAACI 2018 PMID 28748641)
- Asthma control prerequisite for vit initiation (EAACI 2018 PMID 28748641)
- Pediatric isolated cutaneous systemic no vit no auto injector routine very low progression (JTF 2016 PMID 28007086)
- Alpha gal screen for bovine derived products incl some vaccines and medications gelatin cetuximab (Wilson 2019 PMID 30940532)

Monitoring

Regimen monitoring:
- auto injector carry expiry technique at every visit (JTF 2016 PMID 28007086)
- vit post injection observation 30 min (EAACI 2018 PMID 28748641)
- serial baseline tryptase in mastocytosis associated vit (EAACI 2018 PMID 28748641)
- alpha gal specific ige trend annually for tolerance decision (Wilson 2019 PMID 30940532)
- sting re exposure diary and response pattern
- asthma control status each vit visit

Setting (outpatient) monitoring:
- Auto-injector check at every visit
- VIT post-injection observation 30 min
- Serial tryptase if mastocytosis-associated VIT
- Annual review of alpha-gal sIgE trend if applicable

Follow-up plan: Lifelong: trigger avoidance education (Hymenoptera identification + avoidance + tick-bite prevention), auto-injector carry + technique + expiry monitoring. VIT 3-5 y standard, then reassess sting tolerance + tryptase + risk factors; LIFELONG VIT for high-risk groups. Alpha-gal — periodic re-evaluation of sIgE trend; supervised reintroduction discussion only after years of declining titres.
- Close-out criterion: Lifelong plan reviewed; VIT continuation/discontinuation decision documented

Monitoring phase: During VIT — symptom diary, post-injection observation 30 min, watch for systemic reaction during uptitration. Periodic baseline tryptase if mastocytosis suspected. Annual auto-injector check (carry + expiry + technique). For alpha-gal — sIgE level trend over years may decline if tick exposure ceases (some patients tolerate re-introduction with allergist supervision).

Disposition

Current setting: outpatient — Classify reaction grade (local / large local / cutaneous systemic / systemic anaphylaxis), prescribe grade-appropriate therapy + auto-injector + action plan, and refer systemic reactors for venom immunotherapy with lifelong VIT for high-risk groups (JTF 2016 PMID 28007086; EAACI 2018 PMID 28748641)

Disposition criteria:
- Local / large local managed by primary care + supportive Rx
- Cutaneous systemic + systemic anaphylaxis -> allergist for VIT consideration
- Active anaphylaxis -> ED

Escalation triggers (move to higher acuity):
- Active anaphylaxis -> ED + allergy.anaphylaxis.v1
- Elevated baseline tryptase / mastocytosis suspected -> allergy.mast-cell-activation-syndrome.core.v1 + lifelong VIT
- VIT failure (systemic reaction during maintenance) -> reassess venom dose + adjuncts + ddx

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Sting-triggered systemic reaction with airway / CV / two-organ system involvement
- [SEVERE] Baseline tryptase elevated or known mastocytosis in patient with prior systemic sting reaction
- [MODERATE] Alpha-gal-specific IgE positive + history of delayed 3-6h post-mammalian-meat reaction

Citations

- JTF Stinging Insect Hypersensitivity Practice Parameter Update 2016 (Golden DBK et al, Ann Allergy Asthma Immunol 2017-01; PMID 28007086) + EAACI Guidelines on Allergen Immunotherapy: Hymenoptera Venom Allergy (Sturm GJ et al, Allergy 2017-12; PMID 28748641) + Alpha-gal syndrome characterisation (Wilson JM, Commins SP, Platts-Mills TAE et al, J Allergy Clin Immunol Pract 2019-07; PMID 30940532) [PMID:28007086](https://pubmed.ncbi.nlm.nih.gov/28007086/)
- Cited evidence (PMID 28748641) [PMID:28748641](https://pubmed.ncbi.nlm.nih.gov/28748641/)
- Cited evidence (PMID 30940532) [PMID:30940532](https://pubmed.ncbi.nlm.nih.gov/30940532/)

Last reconciled with current guidelines: 2026-05-26.
References
  • JTF Stinging Insect Hypersensitivity Practice Parameter Update 2016 (Golden DBK et al, Ann Allergy Asthma Immunol 2017-01; PMID 28007086) + EAACI Guidelines on Allergen Immunotherapy: Hymenoptera Venom Allergy (Sturm GJ et al, Allergy 2017-12; PMID 28748641) + Alpha-gal syndrome characterisation (Wilson JM, Commins SP, Platts-Mills TAE et al, J Allergy Clin Immunol Pract 2019-07; PMID 30940532) — PMID:28007086
  • Cited evidence (PMID 28748641) — PMID:28748641
  • Cited evidence (PMID 30940532) — PMID:30940532